Advisors at the FDA suggest GSK's RSV vaccine for the elderly, but warn of some safety concerns.

On Wednesday, an independent group of advisors to the FDA recommended GlaxoSmithKline's RSV vaccine for adults 60 and older, though they raised concerns about the vaccine's safety in regards to nervous system disorders.

The safety data on GSK's vaccine was deemed acceptable by ten FDA advisors, but insufficient by two. The panel agreed unequivocally that there was enough evidence to support the vaccine's effectiveness....